EUVIMEDEUVIMED entdecken
Leserbrief

Reconsidering the Association Between GLP-1 Receptor Agonists and Atrial Fibrillation Risk in Chronic Kidney Disease

Wei Chen, Xiqin Wang, Yue Xiao

Cardiovascular Drugs and Therapy · 2026-12 · 40 (6) · 2561-2562

DOI: 10.1007/s10557-026-07939-7 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Cardiovascular Drugs and Therapy, online erschienen am 27.08.2026. Verfasst von Wei Chen und 2 weiteren Autor:innen. Beteiligte Einrichtung: Wenzhou Medical University, Wenzhou, 325035, China. 15657057690@139.com. Die Arbeit nennt 6 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

Atrial fibrillationChronic kidney diseaseGLP-1 receptor agonistsReal-world evidenceSurveillance bias

Autor:innen und Institutionen

  • Wenzhou Medical University, Wenzhou, 325035, China. 15657057690@139.com.
  • Renji College, Wenzhou Medical University, Wenzhou, 325035, China. 15657057690@139.com.
  • Wenzhou Medical University, Wenzhou, 325035, China.

Zitieren

APA

Chen, W., Wang, X., & Xiao, Y. (2026). Reconsidering the Association Between GLP-1 Receptor Agonists and Atrial Fibrillation Risk in Chronic Kidney Disease. Cardiovascular Drugs and Therapy, 40(6), 2561-2562. https://doi.org/10.1007/s10557-026-07939-7

Vancouver

Chen W, Wang X, Xiao Y. Reconsidering the Association Between GLP-1 Receptor Agonists and Atrial Fibrillation Risk in Chronic Kidney Disease. Cardiovascular Drugs and Therapy. 2026;40(6):2561-2562. doi:10.1007/s10557-026-07939-7

BibTeX
@article{Chen2026,
  author = {Chen, Wei and Wang, Xiqin and Xiao, Yue},
  title = {Reconsidering the Association Between GLP-1 Receptor Agonists and Atrial Fibrillation Risk in Chronic Kidney Disease},
  journal = {Cardiovascular Drugs and Therapy},
  year = {2026},
  volume = {40},
  number = {6},
  pages = {2561--2562},
  doi = {10.1007/s10557-026-07939-7}
}
Kostenlos starten →